StreetAlpha.app
Home › Stocks › CHRS

Coherus Oncology, Inc. (CHRS)

$0.37
▼ −4.47%
LAST CLOSE · NOV 20

Coherus Oncology develops and sells LOQTORZI, a cancer medicine, and is developing two other cancer treatment candidates in clinical studies. It last closed at $0.37 on Nov 20, down 4.47% on the day. The next earnings report for CHRS is expected around Tue, Jan 12, 2027. For the quarter ended Sep 2026, CHRS reported EPS of -$0.25 on revenue of $14.3M, with revenue up 23.4% from a year ago. Over its last 8 reports the stock moved an average of 10.9% the session after earnings.

AI Auto Pilots
Is CHRS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CHRS.

Key Stats

Last 12 months
Results
Revenue
$53.6M
+44.4% vs a year ago
Net income
−$135.9M
−187.7% vs a year ago
EPS (diluted)
−$1.00
−175.2% vs a year ago
Gross margin
69.8%
$37.4M gross profit
Valuation
Market cap
$57.1M
154.5M shares
P/E
–
No P/E while losing money
Price to sales
1.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$53.5M
At Sep 30
Shareholder equity
$25.2M
Shares outstanding
154.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $326.6M$326.6MFY2021FY2022: $211.0M$211.0MFY2022FY2023: $257.2M$257.2MFY2023FY2024: $26.4M$26.4MFY2024FY2025: $42.2M$42.2MFY2025

From CHRS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · Time not announced
Reported EPS
-$0.25
Quarter ended Sep 2026
Year ago EPS
-$0.31
Same quarter last year
Revenue
$14.3M
+23.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.44Dec '24Mar 2025: $2.57Mar '25Jun 2025: $2.57Jun '25Sep 2025: -$0.31Sep '25Dec 2025: -$0.34Dec '25Mar 2026: -$0.28Mar '26Jun 2026: -$0.13Jun '26Sep 2026: -$0.25Sep '26Latest -$0.25
Revenue by quarter
Dec 2024: $7.7MDec '24Mar 2025: $7.6MMar '25Jun 2025: $10.3MJun '25Sep 2025: $11.6MSep '25Dec 2025: $12.7MDec '25Mar 2026: $12.3MMar '26Jun 2026: $14.3MJun '26Sep 2026: $14.3MSep '26Latest $14.3M
How CHRS moved after its last 8 reports
Average move the session after a report ±10.9%
Nov 9, 2026After the close−21.6%
Aug 5, 2026After the close−12.8%
May 11, 2026After the close−12.3%
Mar 9, 2026After the close+1.0%
Jan 13, 2026Time not announced+3.0%
Nov 6, 2025After the close−10.1%
Aug 7, 2025After the close−7.1%
May 12, 2025After the close−19.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CHRSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CHRS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CHRS

Technical Analysis

CHRS · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 91% below its 20 day and 161% below its 50 day average. It is 285% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $0.36, and the nearest resistance the Pivot at $0.38.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 21.8%/day
Key levels
$2.6252 week high+608.1%
$1.42200 day average+283.8%
$1.18100 day average+218.9%
$1.09Swing high (Oct 15)+194.6%
$0.9750 day average+162.2%
$0.7120 day average+91.9%
$0.40Pivot R1+8.1%
$0.38Pivot+2.7%
$0.37Last close
$0.3652 week low−2.7%
$0.35Pivot S1−5.4%
Indicators
RSI (14)23.15Oversold below 30Oversold
MACD-0.17Below its signal lineBearish
Stochastic1.7Near the bottom of its rangeOversold
ADX (14)37.4Trending down
Williams %R-98.7Oversold below −80, overbought above −20Oversold
CCI (20)-117.0Oversold below −100, overbought above 100Oversold
Rate of change−52.0%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 21.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CHRS

What happened before

See how CHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CHRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CHRSHow many large options trades hit CHRS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CHRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼56 buying vs 74 selling
  • ▼Held by funds -2.6 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding136147−7.5%
In funds' top 10110.0%
Held by funds42.9%45.5%−2.6 pts
New / increased18 / 3810 / 62−22.2%
Reduced / sold out45 / 2939 / 20+25.4%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CHRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CHRS Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 23, 2025Mats WahlstromDirectorSale99,988$0.74$74K
Every insider buy and sale for CHRS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CHRS insider trades →

From SEC Form 4 filings by CHRS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CHRS is in one of them and how their past CHRS trades turned out.

CHRS in the AI portfolios
Loading…

CHRS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CHRS in an article yet. Here's the latest on the wider market.

CHRS in the news

CHRS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 9
Who traded CHRS · since 2023
Latest 1 filing
$15K – $50KTraded Jan 23, 2023Filed Feb 9, 2023
PersonTypeAmountTradedFiledDelay
Shri ThanedarD · MISell$15K – $50KJan 23, 2023Feb 9, 202317 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Coherus Oncology

Coherus Oncology is a cancer drug company based in Redwood City, California. Its main product is LOQTORZI, an antibody medicine that blocks the PD-1 pathway. It is approved in the United States for nasopharyngeal carcinoma, a cancer of the upper throat, and the company sells it for treating cancer patients. The company is also developing two other cancer treatment candidates in clinical studies, aimed at cancers such as liver, head and neck, and colorectal cancer.

Headquarters
Redwood City, CA
Founded
2010